BioSpace News Archive

HistoSonics, the developer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced the first kidney patient has been treated using the Company’s histotripsy platform.

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that its Chief Medical Officer, Dr Dana Hilt will make an oral presentation to the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (ADPD™ 2023) later today in Gothenburg, Sweden.

Akari Therapeutics, Plc, a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announced that it has entered into definitive agreements with certain institutional investors and accredited investors.

Renovion, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARINA-1 for the prevention of bronchiolitis obliterans syndrome (BOS) progression in adults with a bilateral lung transplant.

Stilla Technologies and Atila BioSystems announced an agreement to market digital PCR kits and assays produced by Atila BioSystems for use on the naica® system.

No one feels sexy when spring allergies hit. Introducing Astepro® Allergy – the only long-lasting nasal spray that starts working in 30 minutes, so allergy sufferers can relieve their allergy symptoms and be more spontaneous in their romantic pursuits.

The American Urological Association announced Stacy Tanaka, MD, as the Editor of AUANews, AUA’s official newsmagazine, published bi-monthly and free to all AUA members.

Pharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries, and Chief Commercial Officer, Stephen Toor, will attend the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days, April 3 - 4, 2023 in New York.

RenovoRx, Inc. announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 1,557,632 shares of the Company’s common stock at a purchase price of $3.21 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced positive first-in-human pharmacokinetic and hematology data from its Phase 1a single and multiple ascending dose trial for its investigational novel BET inhibitor, VYN201.